Skip to Content

Verzenio FDA Approval History

FDA Approved: Yes (First approved September 28, 2017)
Brand name: Verzenio
Generic name: abemaciclib
Dosage form: Tablets
Company: Eli Lilly and Company
Treatment for: Breast Cancer

Verzenio (abemaciclib) is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 indicated for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer.

Development Timeline for Verzenio

Feb 26, 2018Approval Lilly Receives Additional FDA Approval for Verzenio (abemaciclib), as Initial Treatment for Advanced Breast Cancer
Sep 28, 2017Approval FDA Approves Verzenio (abemaciclib) for Certain Advanced or Metastatic Breast Cancers
Jul 12, 2017FDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.